Research Article

The mechanisms of cardiac myopathies, a kinetics approach: Leading review

Gerry A Smith*

Published: 07/16/2020 | Volume 5 - Issue 2 | Pages: 141-152

The normal adult heart is a well maintained machine that has a mechanism for growth replacement of the sarcomere that is lost by natural degeneration. This process ensures the heart has the strength of contraction to function correctly giving blood supply to the whole body.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001101 Cite this Article

References

  1. Holroyde MJ, Robertson SP, Johnson JD, Solaro RJ, Potter JD. The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem. 1980; 25; 255: 11688–11693. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6449512
  2. Smith GA, Dixon HB, Kirschenlohr HL, Grace AA, Metcalfe JC, Vandenberg JI. Ca2+ buffering in the heart: Ca2+ binding to and activation of cardiac myofibrils. Biochem J. 2000; 346 (Pt 2): 393–402. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220865/
  3. Morimoto S and Ohtsuki I. Ca2+ binding to cardiac troponin C in the myofilament lattice and its relation to the myofibrillar ATPase activity. Eur J Biochem. 1994; 226: 597-602. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8001574
  4. Smith GA, Vandenberg JI, Freestone NS and Dixon HBF,The effect of Mg2+ on cardiac muscle function: is CaATP the substrate for priming myofibril cross-bridge formation and Ca2+ re-uptake by the sarcoplasmic reticulum? B J. 2001; 354: 539-551. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1221685/
  5. Donaldson SK, Best PM, Kerrick GL. Characterization of the effects of Mg2+ on Ca2+- and Sr2+-activated tension generation of skinned rat cardiac fibers. J Gen Physiol. 1978; 71: 645–655. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/97362
  6. Hofmann PA, Hartzell HC, Moss RL. Alterations in Ca2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol. 1991; 97: 1141–1163. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1678777
  7. Kampourakis T, Yan Z, Gautel M, Sun YB and Irving M. Myosin binding protein-C activates thin filaments and inhibits thick filaments in heart muscle cells PNAS. 2014; 111: 18763-18768. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25512492
  8. Smith GA. Calcium, actomyosin kinetics, myosin binding protein-c and hypertrophic cardiomyopathy. J Integr Cardiol. 2019; 5: 1-2.
  9. Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019; 16 9: 878. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31888115
  10. van Dijk SJ, Dooijes D, dos Remedios C, Michels M , Lamers JMJ, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy. Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction. Circulation. 2009; 119: 1473–1483. PubMed: https://pubmed.ncbi.nlm.nih.gov/19273718/
  11. Doh CY, Li J, Mamidi R, Stelzer JE. The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2019; 1865: 661-677.
  12. Parbhudayal RY, Garra AR, Götte MJW, Michels M, Pei J, et al. Variable Cardiac Myosin Binding protein-C Expression in the Myofilaments Due to MYBPC3 Mutations in Hypertrophic Cardiomyopathy. J Mol Cell Cardiol. 2018; 123: 59-63. PubMed: https://pubmed.ncbi.nlm.nih.gov/30170119
  13. Harris SP, Bartley CR, Hacker TA, McDonald KS, Douglas PS, et al. Hypertrophic Cardiomyopathy in Cardiac Myosin Binding Protein-C Knockout Mice. Circ Res. 2002; 90: 594-601. PubMed: https://pubmed.ncbi.nlm.nih.gov/11909824
  14. Harris SP, Rostkova E, Gautel M, Moss RL. Binding of myosin binding protein-C to myosin subfragment S2 affects contractility independent of a tether mechanism. Circ Res.2004; 95. 930–936.
  15. Razumova MV, Bezold KL, Tu AY, Regnier M, Harris SP. Contribution of the Myosin Binding Protein C Motif to Functional Effects in Permeabilized Rat Trabeculae. JGen Physiol. 2008; 132: 575–585. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18955596
  16. Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 2015; 573: 188-197. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660134/
  17. Harris SP, Belknap B, Van Sciver RE, White HD, Galkin VE. C0 and C1 N-terminal Ig domains of myosin binding protein C exert different effects on thin filament activation. Proc Natl Acad Sci U S A. 2016; 113: 1558-1563.
  18. Mettikolla P, Calander N, Luchowski R, Gryczynski I, Gryczynski Z, et al. Cross-bridge Kinetics in Myofibrils Containing Familial Hypertrophic Cardiomyopathy R58Q Mutation in the Regulatory Light Chain of Myosin. J Theor Biol. 2011; 284: 71-81. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152379/
  19. Lang R, Gomes AV, Zhao J, Housmans PR, Miller T, et al. Functional Analysis of a Troponin I (R145G) Mutation Associated with Familial Hypertrophic Cardiomyopathy. J Biol Chem. 2002; 277: 11670-11678. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11801593
  20. Davis J, Wen H, Edwards T, Joseph M, Metzger JM. Thin Filament Disinhibition by Restrictive Cardiomyopathy Mutant R193H Troponin I Induces Ca2+-Independent Mechanical Tone and Acute Myocyte Remodeling. Circulation Res. 2007; 100: 1494–1502. PubMed: https://pubmed.ncbi.nlm.nih.gov/17463320/
  21. Davis J, Wen H, Edwards T, Joseph M, Metzger JM. Allele and Species Dependent Contractile Defects by Restrictive and Hypertrophic Cardiomyopathy-Linked Troponin I Mutants. J Mol Cell Cardiol. 2008; 44: 891-904. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18423659
  22. Du J, Liu J, Feng HZ, Hossain MM, Gobara N, et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI Am J Physiol Heart Circ Physiol. 2008; 294: H2604–H2613. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769498/
  23. Zhang J, Kumar A, Stalker HJ, Virdi G, Ferrans VJ, et al. Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy. Clin Genet. 200; 59: 248-256.
  24. Sheng JJ, Feng HZ, Pinto JR, Wei H, Jin JP. Increases of desmin and α-actinin in mouse cardiac myofibrils as a response to diastolic dysfunction. J Mol Cell Cardiol. 2016; 99: 218–229. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26529187
  25. Parvatiyar MS, Pinto JR, Dweck D, Potter JD. Cardiac Troponin Mutations and Restrictive Cardiomyopathy. J Biomed Biotech. 2010; 350706. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896668/
  26. Jean-Charles PY, Li YJ, Nan CL, Huang XP. Monitoring Editor: Xiao Y-F. Insights into restrictive cardiomyopathy from clinical and animal studies. J Geriatr Cardiol. 2011; 8: 168–183. PubMed: https://pubmed.ncbi.nlm.nih.gov/22783303/
  27. Wen Y, Xu Y, Wang Y, Pinto JR, Potter JD, Kerrick WGL. Functional Effects of a Restrictive Cardiomyopathy linked Cardiac Troponin I mutation (R145W) in Transgenic Mice. J Mol Biol. 2009; 392: 1158–1167. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774805/
  28. Gomes AV, Liang J, Potter JD. Mutations in Human Cardiac Troponin I That Are Associated with Restrictive Cardiomyopathy Affect Basal ATPase Activity and the Calcium Sensitivity of Force Development. J Biol Chem. 2005; 280: 30909-30915. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15961398
  29. Dyer EC, Jacques AM, Hoskins AC, Ward DG, Gallon CE, et al. Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle. Circulation: Heart Failure. 2009; 2: 456–464.
  30. Swindle N, Albury ANJ, Baroud B, Burney M, Svetlana B, et al. Molecular and Functional Consequences of Mutations in the Central Helix of Cardiac Troponin C. Arch Biochem Biophys. 2014; 548: 46–53. PubMed: https://pubmed.ncbi.nlm.nih.gov/24650606/
  31. Keller DI, Coirault C, Rau T, Cheav T, Weyand M, et al. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol. 2004; 36: 355-62. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440471/
  32. Kraft T, Witjas-Paalberends ER, Boontje NM, Tripathi S, Brandis A, et al Familial hypertrophic cardiomyopathy: Functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol. 2013; 57: 13-22. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23318932
  33. Spudich JA, Aksel T, Bartholomew SR, Nag S, Kawana M, et al. Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin. J Exper Biol. 2016; 219: 161-167.
  34. Nag S, Sommese RF, Ujfalusi Z, Combs A, Langer S, et al. Parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. Sci Adv. 2015; 1: e1500511.
  35. Sarkar SS, Trivedi DV, Morck MM, Adhikari AS, Pasha SN, et al. The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin Sci Adv. 2020; 6: eaax0069. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32284968
  36. Huang W, Liang J, Yuan CC, Kazmierczak K, Zhou Z, et al. Novel Familial Dilated Cardiomyopathy Mutation in MYL2 Affects the Structure and Function of Myosin Regulatory Light Chain. FEBS J. 2015; 282: 2379–2393. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472530/
  37. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac Dysfunction in Hypertrophic Cardiomyopathy Mutant Tropomyosin Mice Is Transgene-Dependent, Hypertrophy-Independent, and Improved by β-Blockade. Circulation Res. 2002; 91: 255–262.
  38. Michele DE, Albayya FP, Metzger JM. Direct, Convergent Hypersensitivity of Calcium-Activated Force Generation Produced by Hypertrophic Cardiomyopathy Mutant Alpha-Tropomyosins in Adult Cardiac Myocytes. Nat Med. 1999; 5: 1413-1417. PubMed: https://pubmed.ncbi.nlm.nih.gov/10581085/
  39. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, et al. Mouse Model of a Familial Hypertrophic Cardiomyopathy Mutation in α-Tropomyosin Manifests Cardiac Dysfunction. Circ. Res 1999; 85: 47–56. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10400910
  40. Chang AN, Harada K, Ackerman MJ, Potter JD. Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. J Biol Chem. 2005; 280: 34343-34349. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16043485
  41. Gupte TM, Haque F, Gangadharan B, Sunitha MS, Mukherjee S, et al. Mechanistic Heterogeneity in Contractile Properties of α-Tropomyosin (TPM1) Mutants Associated with Inherited Cardiomyopathies. J Biol Chem. 2015; 290: 7003-7015. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358124/
  42. Rajan S, Ahmed RPH, Jagatheesan G, Petrashevskaya N, Boivin GP, et al. Dilated Cardiomyopathy Mutant Tropomyosin Mice Develop Cardiac Dysfunction With Significantly Decreased Fractional Shortening and Myofilament Calcium Sensitivity. Circulation Res. 2007; 101: 205–214. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17556658
  43. Song W, Dyer E, Stuckey D, Leung MC, Memo M, et al. Investigation of a transgenic mouse model of familial dilated cardiomyopathy. J. Mol Cell Cardiol. 2010; 49: 380–389. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20600154
  44. Hernandez OM, Szczesna-Cordary D, Knollmann BC, Miller T, Bell M, et al. F110I and R278C Troponin T Mutations That Cause Familial Hypertrophic Cardiomyopathy Affect Muscle Contraction in Transgenic Mice and Reconstituted Human Cardiac Fibers. J Biol Chem. 2005; 280: 37183-37194. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16115869
  45. Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, et al. Ca2+-desensitizing effect of a deletion mutation ΔK210 in cardiac troponin T that causes familial dilated cardiomyopathy PNAS. 2002; 99: 913-918.
  46. Sfichi-Duke L, Garcia-Cazarin ML, Sumandea CA, Sievert GA, Balke CW, et al. Cardiomyopathy-causing Deletion K210 in Cardiac Troponin T Alters Phosphorylation Propensity of Sarcomeric Proteins. J Mol Cell Cardiol. 2010; 48: 934-942.
  47. Venkatraman G, Gomes AV, Kerrick WGL, Potter JD. Characterization of Troponin T Dilated Cardiomyopathy Mutationsin the Fetal Troponin Isoform. J Biol Chem. 2005; 280: 17584–17592. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15623536
  48. Jones KMD, Koh Y, Weller RS, Turna RS, Ahmad F, et al. Pathogenic Troponin T Mutants With Opposing Effects on Myofilament Ca 2+ Sensitivity Attenuate Cardiomyopathy Phenotypes in Mice. Arch Biochem Biophys. 2019; 661: 125-131. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30445044
  49. Sommese RF, Nag S, Sutton S, Miller SM, Spudich JA, et al. Effects of Troponin T Cardiomyopathy Mutations on the Calcium Sensitivity of the Regulated Thin Filament and the Actomyosin Cross-Bridge Kinetics of Human β-Cardiac Myosin. PLOS ONE. 2013; 8: e83403. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867432/
  50. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzeri RM. Myofibrillar Calcium Sensitivity of Isometric Tension Is Increased in Human Dilated cardiomyopathies Role of Altered b-adrenergically Mediated Protein Phosphorylation. J Clin Invest. 1996; 98: 167–176. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8690789
  51. Lu QW, Wu XY, Morimoto S. Inherited cardiomyopathies caused by troponin mutations. J Geriatr Cardiol. 2013; 10: 91–101. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23610579
  52. de A Marques M, de Oliveira GAP. Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. Front Physiol. 2016; 7: 429. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27721798